Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with metastatic colorectal cancer that harbors KRAS mutations in exon 2 do not benefit from anti-epidermal growth factor receptor (EGFR) therapy. Other activating RAS mutations may also be negative predictive biomarkers for anti-EGFR therapy. METHODS: In this prospective-retrospective analysis, we assessed the efficacy and safety of panitumumab plus oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) as compared with FOLFOX4 alone, according to RAS (KRAS or NRAS) or BRAF mutation status. A total of 639 patients who had metastatic colorectal cancer without KRAS mutations in exon 2 had results for at least one of the following: KRAS exon 3 or 4; NRAS exon 2, 3, or 4; or BRAF exon 15. The overall rate of ascertainment of RAS status was 90%. RESULTS: Among 512 patients without RAS mutations, progression-free survival was 10.1 months with panitumumab-FOLFOX4 versus 7.9 months with FOLFOX4 alone (hazard ratio for progression or death with combination therapy, 0.72; 95% confidence interval [CI], 0.58 to 0.90; P=0.004). Overall survival was 26.0 months in the panitumumab-FOLFOX4 group versus 20.2 months in the FOLFOX4-alone group (hazard ratio for death, 0.78; 95% CI, 0.62 to 0.99; P=0.04). A total of 108 patients (17%) with nonmutated KRAS exon 2 had other RAS mutations. These mutations were associated with inferior progression-free survival and overall survival with panitumumab-FOLFOX4 treatment, which was consistent with the findings in patients with KRAS mutations in exon 2. BRAF mutations were a negative prognostic factor. No new safety signals were identified. CONCLUSIONS: Additional RAS mutations predicted a lack of response in patients who received panitumumab-FOLFOX4. In patients who had metastatic colorectal cancer without RAS mutations, improvements in overall survival were observed with panitumumab-FOLFOX4 therapy. (Funded by Amgen and others; PRIME ClinicalTrials.gov number, NCT00364013.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Consistent with BRAFV600E mutation, signaling independent of upstream input, anti-EGFR therapy is not useful in patients with BRAFV600E tumors as single agents [93] or in combination with chemotherapy [94].”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [94]
In the citing paper
“Additional rare mutations of KRAS, as well as mutations of NRAS, have been associated with primary resistance to treatment.”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [35]
In the citing paper
“Further analysis of molecular subgroups in this study showed that adding panitumumab significantly improved mPFS and mOS in the non-mutated KRAS group but was ineffective in patients with KRAS non-exon 2 mutations [15].”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [15]
In the citing paper
“Genetic analysis has shown that 98% of RAS mutations that cause cancer are concentrated in three residues: G12, G13, and Q61.”
From The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives (2025) · cites this paper as [18]
In the citing paper
“The most frequently detected mutations in codons 12 and 13—namely G12V (incidence: 20–25%), G12S (5–7%), G12R (3–5%), G12A (3–5%), and G13D (15–20%)—are also clinically relevant, with their prevalence varying by tumor type [16,17,18].”
From The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives (2025) · cites this paper as [18]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877 · cited 5×
“Worst grade of 5 14 (5) 16 (6) 30 (6) 19 (7) 10 (4) 29 (5)”
InfluentialSelf-citationWild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207 · cited 4×
“Not determined 4/320 (1) 8/321 (2) 12/641 (2)”
InfluentialSelf-citationCOSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Forbes, S. A., Bindal, N., Bamford, S., Cole, C., Kok, C. Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq929 · Cited by 2,278 · cited 3×
“Not serious 48 (19) 28 (11) 76 (15) 50 (19) 24 (9) 74 (14)”
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144 · cited 1×
“Not serious 48 (19) 28 (11) 76 (15) 50 (19) 24 (9) 74 (14)”
Self-citationVan Cutsem, E., Köhne, C.-H., Láng, I., Folprecht, G., Nowacki, M. P., Cascinu, S., Shchepotin, I., Maurel, J., Cunningham, D., Tejpar, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.5091 · Cited by 1,882
Self-citationDouillard, J.-Y., Siena, S., Cassidy, J., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4860 · Cited by 1,809 · cited 2×
“Not determined 4/320 (1) 8/321 (2) 12/641 (2)”
Self-citationWild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0786 · Cited by 1,591
Self-citationRas oncogenes: split personalities
Karnoub, A. E., & Weinberg, R. A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2438 · Cited by 1,467 · cited 3×
“Worst grade of 5 14 (5) 16 (6) 30 (6) 19 (7) 10 (4) 29 (5)”
Peeters, M., Price, T. J., Cervantes, A., Sobrero, A. F., Ducreux, M., Hotko, Y., André, T., Chan, E., Lordick, F., Punt, C. J. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.6055 · Cited by 1,005
Self-citation
Research works printed but not linked: 2
- Wojcik P, 2008, Pol J Pathol, 59, 93
- Yuen ST, 2002, Cancer Res, 62, 6451
Cited by
Items 901–1,000 of 1,008
Stucchi, E., Bartolini, M., Airoldi, M., Fazio, R., Daprà, V., Mondello, G., Prete, M. G., Puccini, A., & Santoro, A. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2336069 · Cited by 20
Exploring Predictive and Prognostic Biomarkers in Colorectal Cancer: A Comprehensive Review
Ashouri, K., Wong, A., Mittal, P., Torres‐Gonzalez, L., Lo, J. H., Soni, S., Algaze, S. D., Khoukaz, T., Zhang, W., Yang, Y., et al. (2024) · Cancers · doi:10.3390/cancers16162796 · Cited by 24
“Multiple studies, including the phase 3 CRYSTAL and PRIME trials, have demonstrated that KRAS / NRAS mutations predict a poor response to combination chemotherapy with EGFR inhibitors [14,15].”
BackgroundRecent applications of chemosensitivity tests for colorectal cancer treatment
Yoon, Y. S., & Kim, J. C. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i44.16398 · Cited by 22
Stein, A., Atanackovic, D., Hildebrandt, B., Stübs, P., Brugger, W., Hapke, G., Steffens, C.-C., Illerhaus, G., Bluemner, E., Stöhlmacher, J., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.299 · Cited by 21
“Notably, median overall survival (OS) can now be as long as 30 months in molecularly or clinically selected patients with current treatment regimen (Douillard et al, 2013; Heinemann et al, 2014; Loupakis et al, 2014; Venook et al, 2014).”
BackgroundTherapeutic Approaches to RAS Mutation
Scott, A. J., Lieu, C. H., & Messersmith, W. A. (2016) · The Cancer Journal · doi:10.1097/ppo.0000000000000187 · Cited by 24
Janowski, E., Timofeeva, O. A., Chasovskikh, S., Goldberg, M., Kim, A., Banovac, F., Pang, D., Dritschilo, A., & Unger, K. R. (2016) · Oncology Reports · doi:10.3892/or.2016.5284 · Cited by 19
“Multiple clinical trials have confirmed the lack of clinical benefit of anti-EGFR therapy against RAS mutant tumors (32,33).”
BackgroundReporting and communication of randomisation procedures is suboptimal in veterinary trials
Girolamo, N. D., Giuffrida, M. A., Winter, A. L., & Reynders, R. M. (2017) · Veterinary Record · doi:10.1136/vr.104035 · Cited by 22
Peeters, M., Forget, F., Karthaus, M., Valladares‐Ayerbes, M., Zaniboni, A., Demonty, G., Guan, X., & Rivera, F. (2018) · ESMO Open · doi:10.1136/esmoopen-2017-000297 · Cited by 20
“bm jcom / E S M O O pen: frst pulished as 10.(11)36/esm oopen17-000297 on 24 F ebuary 218.”
BackgroundSelf-citationThe extended spectrum of RAS‐MAPK pathway mutations in colorectal cancer
Costigan, D. C., & Dong, F. (2019) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22813 · Cited by 24
Giordano, G., Parcesepe, P., Bruno, G., Piscazzi, A., Lizzi, V., Remo, A., Pancione, M., D'Andrea, M. R., Santis, E. D., Coppola, L., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147717 · Cited by 19
“A combination of panitumumab and chemotherapy in RAS wild-type populations is a standard of care in mCRC first-line therapy [9].”
BackgroundLiu, L., Erickson, N. T., Ricard, I., von Weikersthal, L. F., Lerch, M. M., Decker, T. W., Kiani, A., Kaiser, F., Heintges, T., Kahl, C., et al. (2021) · International Journal of Cancer · doi:10.1002/ijc.33775 · Cited by 20
The Role of Anti-EGFR Monoclonal Antibody in mCRC Maintenance Therapy
Yuan, M., Wang, Z., Lv, W., & Pan, H. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.870395 · Cited by 23
“To date, several retrospective, non-prespecified analyses of randomized clinical trials have confirmed that the pan-RAS mutation acts as a negative predictor for anti-EGFR therapy (Douillard et al., 2013; Heinemann et al., 2014).”
BackgroundAdenoma and carcinoma components in colonic tumors show discordance for KRAS mutation
Hershkovitz, D., Simon, E., Bick, T., Prinz, E., Noy, S., Sabo, E., Ben‐Izhak, O., & Vieth, M. W. (2014) · Human Pathology · doi:10.1016/j.humpath.2014.05.005 · Cited by 23
“Moreover, recent analysis of large clinical trials suggests a detrimental effect of anti-EGFR treatment for patients with RAS mutations [7].”
BackgroundSiena, S., Tabernero, J. M., Bodoky, G., Cunningham, D., Rivera, F., Ruff, P., Canon, J.-L. R., Koukakis, R., Demonty, G., Hechmati, G., et al. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000041 · Cited by 19
“04) in patients with mCRC WT for KRAS and NRAS exons 2–4 (RAS WT).(9) In addition, more patients receiving panitumumab+FOLFOX4 vs FOLFOX4 had ≥30% tumour shrinkage at week 8, while objective response rate, duration of response and depth of response were also improved in the panitumumab group.”
MethodSelf-citationTabernero, J., Taieb, J., Fakih, M., Prager, G. W., Van Cutsem, E., Ciardiello, F., Mayer, R. J., Amellal, N., Skanji, D., Calleja, E., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.102945 · Cited by 18
Self-citationScott, A. J., Basu Mallick, A., Dotan, E., Cohen, S. J., Gold, P. J., Hochster, H. S., Subramaniam, S., Barzi, A., Watts, G. S., Blatchford, P. J., et al. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0169 · Cited by 18
Troiani, T., Napolitano, S., Martini, G., Martinelli, E., Cardone, C., Normanno, N., Vitagliano, D., Morgillo, F., Fenizia, F., Lambiase, M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0211 · Cited by 18
“In particular, with the extended RAS analysis that covers exons 2,3,4 mutations for KRAS and NRAS genes the benefit of anti-EGFR mAbs to first-line FOLFIRI chemotherapy for the all-RAS wild-type patients has been translated in a further improvement of overall survival (6-10).”
BackgroundLu, H., Lin, J.-K., Chen, W.-S., Jiang, J., Yang, S.-H., Lan, Y., Lin, C., Chang, S., & Teng, H. (2016) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.12469 · Cited by 19
Chen, C. T., Bartolomeo, M. D., Corallo, S., Strickler, J. H., & Goyal, L. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280871 · Cited by 20
Sastre, J., Alfonso, P. G., Viéitez, J. M., Cano, M. T., Rivera, F., Zoilo, J. J. R., Salud, A., Quintero, G., Robles-Díaz, L., Safont, M. J., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100062 · Cited by 20
“Sex, n (%) Male 133 (68) 31 (71) 164 (68) Female 63 (32) 13 (30) 76 (32) ECOG performance status, n (%) 0 111 (56) 29 (66) 140 (58) 1 85 (43) 15 (34) 100 (42) Tumour localisation, n (%) Colon 117 (60) 32 (73) 149 (62) Rectum 59 (30) 6 (14) 65 (27) Colorectal 20 (10) 6 (14) 26 (11) Site of primary tumour, n (%) Left co…”
Self-citationCost Estimates and Economic Implications of Expanded RAS Testing in Metastatic Colorectal Cancer
Kircher, S. M., Mohindra, N. A., & Nimeiri, H. S. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0252 · Cited by 20
Anti-EGFR MoAb treatment in colorectal cancer: limitations, controversies, and contradictories
Cheng, L., Ren, W., Xie, L., Li, M., Liu, J., Hu, J. Y., Liu, B., & Qian, X. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2489-6 · Cited by 23
“Besides, these mutations were associated with inferior PFS and OS in terms of panitumumab–FOlFOX4 treatment compared with FOlFOX4 alone, which was in consistence with the findings of patients with mutations of KRAS exon2 [24].”
ResultGill, S., Dowden, S. D., Colwell, B., Collins, L. L., & Berry, S. R. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.10.002 · Cited by 20
A novel antimetabolite: TAS-102 for metastatic colorectal cancer
Miyamoto, Y., Lenz, H., & Baba, H. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1133285 · Cited by 20
“Biological agents have further increased the effect of cytotoxic therapy, including bevacizumab [13-15], ziv-aflibercept [16], cetuximab [17, 18] and panitumumab [19, 20] and”
Bendell, J. C., Zakari, A., Peyton, J. D., Boccia, R. V., Moskowitz, M., Gian, V. G., Lipman, A. J., Waterhouse, D. M., LoCicero, R., Earwood, C., et al. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0439 · Cited by 18
“After the protocol was initiated, new findings were published indicating that RAS mutations outside of KRAS exon 2 are also associatedwith inferior survivalwith combinationpanitumumab and oxaliplatin-based therapy [6].”
BackgroundAzuara, D., Santos, C., López‐Doriga, A., Grasselli, J., Nadal, M., Sanjuán, X., Marín, F., Vidal, J., Montal, R., Moreno, V. R., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0820 · Cited by 20
Self-citationLi, Z.-Z., Wang, F., Zhang, Z.-C., Wang, F., Zhao, Q., Zhang, D.-S., Wang, F.-H., Wang, D., Luo, H., He, M.-M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8541 · Cited by 20
“6% and 7% [8, 37–39].”
Pietrantonio, F., Bartolomeo, M. D., Cotsoglou, C., Mennitto, A., Berenato, R., Morano, F., Coppa, J. C., Perrone, F., Iacovelli, R., Milione, M., et al. (2016) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2016.09.007 · Cited by 19
Mind the gap: An analysis of foregone health gains from unfunded cancer medicines in New Zealand
Evans, J., Laking, G. R., Strother, R. M., Wang, T., Metcalfe, S., Blick, G., Pauls, R., & Crausaz, S. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2016.10.004 · Cited by 18
“respond to first-line chemotherapy PRIME study 20050203 [40] – randomized, open label, phase 3 FOLFOX”
Wang, Y., Wang, H., Jiang, Y., Zhang, Y., & Wang, X. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.02.097 · Cited by 18
Santos, C., Azuara, D., García‐Carbonero, R., Alfonso, P., Carrato, A., Elez, M. E., Gómez, A., Losa, F., Montagut, C. O., Massutí, B., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0153 · Cited by 18
“The PRIME study used Sanger sequencing and WAVE-based SURVEYOR Scan Kits from Transgenomic for RAS and BRAF testing and detected 52% RAS-mutated tumors (2).”
BackgroundMethodSelf-citationRole of circulating tumor DNA in the management of patients with colorectal cancer
Moati, É., Taly, V., Didelot, A., Perkins, G., Blons, H., Taïeb, J., Laurent‐Puig, P., & Zaanan, A. (2018) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2018.03.002 · Cited by 21
Franczak, C., Dubouis, L., Gilson, P., Husson, M., Rouyer, M., Demange, J., Leroux, A., Merlin, J., & Harlé, A. (2019) · PLoS ONE · doi:10.1371/journal.pone.0212801 · Cited by 18
Alfonso, P. G., García‐Carbonero, R., García‐Foncillas, J., Pérez‐Segura, P., Salazar, R., Vera, R., y Cajal, S. R., Hernández‐Losa, J., Landolfi, S., Musulén, E., et al. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-020-02357-z · Cited by 21
“Currently available technologies for mutational analysis of the KRAS and NRAS genes have not been significantly modified compared to the last guide [61, 62], except for the incorporation of the mutational status of the BRAF gene [25], as reflected in Table 2.”
MethodThe Role of BRAF in Metastatic Colorectal Carcinoma–Past, Present, and Future
Djanani, A. M., Eller, S., Öfner, D., Troppmair, J., & Maglione, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239001 · Cited by 20
“Another important finding was, that the negative predictive value for PFS and OS observed in the patient group with either RAS or BRAF mutations was driven by the RAS-mutated patients [88,89].”
ResultGUCY2C as a biomarker to target precision therapies for patients with colorectal cancer
Lisby, A., Flickinger, J. C., Bashir, B., Weindorfer, M., Shelukar, S., Crutcher, M. M., Snook, A. E., & Waldman, S. A. (2021) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2021.1876518 · Cited by 21
“tumor response and overall survival in patients with wild-type tumors, as validated by both CRYSTAL [68] and PRIME [45]”
BackgroundMethodTembuyser, L., & Dequeker, E. M. C. (2015) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-015-1839-z · Cited by 24
“tations is used to predict a lack of responsiveness to antiEGFR therapy [9, 10].”
MethodMolecular Markers Predictive of Chemotherapy Response in Colorectal Cancer
Shiovitz, S., & Grady, W. M. (2015) · Current Gastroenterology Reports · doi:10.1007/s11894-015-0431-7 · Cited by 18
Phelip, J., Mineur, L., de la Fouchardière, C., Chatelut, É., Quesada, J. L., Roblin, X., Pezet, D., Mendoza, C., Buc, E., & Rivoire, M. L. (2016) · Annals of Surgical Oncology · doi:10.1245/s10434-015-5072-4 · Cited by 18
Pander, J., van Huis‐Tanja, L. H., Böhringer, S., van der Straaten, T., Gelderblom, H. A. J., Punt, C. J. A., & Guchelaar, H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0131091 · Cited by 18
Gene heterogeneity in metastasis of colorectal cancer to the lung
Hou, J., Zhang, Y., & Zhu, Z. (2016) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2016.08.034 · Cited by 20
Adua, D., Fabio, F. D., Ercolani, G., Fiorentino, M., Gruppioni, E., Altimari, A., Llimpe, F. L. R., Normanno, N., Pinna, A. D., & Pinto, C. (2017) · Molecular and Clinical Oncology · doi:10.3892/mco.2017.1270 · Cited by 18
“Although biomarkers to select patients responding to anti-VEGF mAbs are not yet available, mutations in exons 2, 3 and 4 of the Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) and neuroblastoma RAS viral oncogene homolog (NRAS) genes are predictive of resistance to anti-EGFR mAbs, whereas the…”
Wang, X., Wei, Q., Gao, J., Li, J., Li, J., Gong, J., Li, Y., & Shen, L. (2017) · 癌症:英文版 · doi:10.1186/s40880-017-0247-y · Cited by 18
Toward a Tiered Model to Share Clinical Trial Data and Samples in Precision Oncology
Broes, S., Lacombe, D. A., Verlinden, M., & Huys, I. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00006 · Cited by 20
“However it took more than 3 years before these new findings were picked up by the industry, to re-analyze the original trial data, and to confirm the result (62).”
BackgroundColorectal Liver Metastases: Does the Future of Precision Medicine Lie in Genetic Testing?
Barbon, C., Margonis, G. A., Andreatos, N., Rezaee, N., Sasaki, K., Buettner, S., Damaskos, C., Pawlik, T. M., He, J. P., Wolfgang, C. L., et al. (2018) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-018-3766-1 · Cited by 19
“Given this high propensity for recurrence, treatment selection can be challenging for patients with colorectal liver metastasis.(14) To this point, the possible role of biomarkers as guides to both prognosis and treatment is presently being explored.”
BackgroundHolch, J. W., Ricard, I., Stintzing, S., von Weikersthal, L. F., Decker, T. W., Kiani, A., Vehling‐Kaiser, U., Heintges, T., Kahl, C., Kullmann, F., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.10.001 · Cited by 18
Xie, W., Xie, L., & Song, X. (2019) · Cancer Medicine · doi:10.1002/cam4.1989 · Cited by 19
Osumi, H., Shinozaki, E., Nakamura, Y., Esaki, T., Yasui, H., Taniguchi, H., Satake, H., Sunakawa, Y., Komatsu, Y., Kagawa, Y., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50026-4 · Cited by 17
“they are ineffective against RAS MT mCRC 5,6 .”
EGFR: New Insights on Its Activation and Mutation in Tumor and Tumor Immunotherapy
Gu, Y., He, H., Qiao, S., Shao, Y., Wang, L., Zhang, Z., Zhang, L., & Zhou, F. (2025) · Advanced Science · doi:10.1002/advs.202505785 · Cited by 25
“Cold” colorectal cancer faces a bottleneck in immunotherapy
Liu, J., Yang, M., Bai, J., Liu, Z., & Wang, X. (2023) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v15.i2.240 · Cited by 23
Surgical Resection in Colorectal Liver Metastasis: An Umbrella Review
Milazzo, M., Todeschini, L., Caimano, M., Mattia, A., Cristin, L., Martinino, A., Bianco, G., Spoletini, G., & Giovinazzo, F. (2024) · Cancers · doi:10.3390/cancers16101849 · Cited by 22
Subclonal response heterogeneity to define cancer organoid therapeutic sensitivity
Kratz, J. D., Rehman, S., Johnson, K. A., Gillette, A. A., Sunil, A., Favreau, P. F., Pasch, C. A., Miller, D. D., Zarling, L. C., Yeung, A. H., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-96204-2 · Cited by 21
Sunakawa, Y., Yang, D., Moran, M., Astrow, S. H., Tsuji, A., Stephens, C. L., Zhang, W., Cao, S., Takahashi, T., Denda, T., et al. (2016) · Cancer Biology & Therapy · doi:10.1080/15384047.2016.1178426 · Cited by 18
Bianchi, A. S., Amatu, A., Bonazzina, E. F., Stabile, S., Giannetta, L. G., Cerea, G., Schiavetto, I., Bencardino, K. B., Funaioli, C., Ricotta, R., et al. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0505-6 · Cited by 17
Self-citationPathak, S., Sushmitha, S., Banerjee, A., Marotta, F., Gopinath, M., Murugesan, R., Zhang, H., Bhavani, B., Girigoswami, A., Sollano, J. D., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22471 · Cited by 17
“Again in 2013, comparison of panitumumab-FOLFOX-4 therapy with WT versus MT KRAS was performed [11].”
BackgroundMethodInfluentialRamon, L., David, C., Fontaine, K., Lallet, E., Marcaillou, C., Martin‐Lannerée, S., Decaulne, V., Vazart, C., Gélibert, A.-H., Abdelali, R. B., et al. (2018) · Biomarker Insights · doi:10.1177/1177271918763357 · Cited by 17
Pauw, I. D., Lardon, F., den Bossche, J. V., Baysal, H., Pauwels, P., Peeters, M., Vermorken, J. B., & Wouters, A. (2019) · Cancers · doi:10.3390/cancers11010098 · Cited by 19
“2 months with chemotherapy alone, respectively [9,10].”
Galbiati, S., Damin, F., Ferraro, L., Soriani, N., Burgio, V., Ronzoni, M., Gianni, L., Ferrari, M., & Chiari, M. (2019) · Cells · doi:10.3390/cells8080769 · Cited by 18
“In this study, we also reported the death of patient number 2 that presented the V600E BRAF mutation and a right-sided colon cancer both indicators of worse prognosis [17,18].”
BackgroundEffectiveness of Vigna unguiculata seed extracts in preventing colorectal cancer
Panzeri, D., Guzzetti, L., Sacco, G., Tedeschi, G., Nonnis, S., Airoldi, C., Labra, M., Fusi, P. A., Forcella, M. E., & Regonesi, M. E. (2020) · Food & Function · doi:10.1039/d0fo00913j · Cited by 19
Dual inhibition of VEGF and PARP suppresses KRAS-mutant colorectal cancer
Zhong, L., Wang, R., Wang, Y., Peng, S., Ma, Y., Ding, S., Yang, H., Chen, S., Luo, X., & Wang, W. (2020) · Neoplasia · doi:10.1016/j.neo.2020.06.001 · Cited by 21
What Is Known about Theragnostic Strategies in Colorectal Cancer
Parisi, A., Porzio, G., Pulcini, F., Cannita, K., Ficorella, C., Mattei, V., & Monache, S. D. (2021) · Biomedicines · doi:10.3390/biomedicines9020140 · Cited by 17
“Moreover, as anti-EGFR therapy with cetuximab and panitumumab is approved for wild-type RAS mCRC and KRAS and BRAF are considered effective predictors of anti-EGFR therapy [35,36], ctDNA detection could represent an alternative tool for the selection of anti-EGFR treatment due to its correlation with RAS mutational st…”
BackgroundFOLFIRINOX Bevacizumab Is a Promising Therapy for Chemorefractory Metastatic Colorectal Cancer
Chaix, M., Vincent, J., Lorgis, V., & Ghiringhelli, F. (2014) · Oncology · doi:10.1159/000361031 · Cited by 17
Panitumumab safety for treating colorectal cancer
Stremitzer, S., Sebio, A., Stintzing, S., & Lenz, H. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.915024 · Cited by 20
“In metastatic CRC, panitumumab has demonstrated efficacy in RAS wt patients in first, second and third line when added to chemotherapy or when administered as monotherapy, thereby being a valuable agent in the armamentarium against this disease [9,11,15].”
BackgroundResultInfluentialCarrasco, J., Gizzi, M., Pairet, G., Lannoy, V., Lefesvre, P., Gigot, J. F., Hubert, C., Jouret‐Mourin, A., Humblet, Y., Canon, J.-L., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.321 · Cited by 17
Self-citationKRAS and BRAF mutational status in colon cancer from Albanian patients
Martinetti, D., Costanzo, R., Kadare, S., Alimehmeti, M., Colarossi, C., Canzonieri, V., Berretta, M., & Memeo, L. (2014) · Diagnostic Pathology · doi:10.1186/s13000-014-0187-7 · Cited by 17
“Different somatic missense mutations in codons 12, 13, 61 and 146 are relevant for therapeutic efficacy of anti-EGFR therapy [10-14].”
BackgroundKoukakis, R., Gatta, F., Hechmati, G., & Siena, S. (2016) · Quality of Life Research · doi:10.1007/s11136-016-1288-4 · Cited by 18
“has been shown to improve overall survival (OS) versus FOLFOX alone [3] and versus FOLFOX plus bevacizumab [7] in patients with WT RAS or KRAS mCRC.”
BackgroundSelf-citationMatsunaga, M., Kaneta, T., Miwa, K., Ichikawa, W., Fujita, K., Nagashima, F., Furuse, J., Kage, M., Akagi, Y., & Sasaki, Y. (2016) · Oncology Letters · doi:10.3892/ol.2016.4576 · Cited by 21
“Second, more sensitive and specific methods than those used in our study, including the BEAMing method (31) and WAVEbased Surveyor Scan kits (32), are available to detect KRAS mutation status.”
Němeček, R., Berkovcová, J., Radová, L., Kazda, T., Mlčochová, J., Vychytilova‐Faltejskova, P., Slabý, O., & Svoboda, M. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s102891 · Cited by 17
“Mutations in oncogenes, KRAS or NRAS (overall called “RAS”), occur in ~50% of patients with metastatic colorectal cancer (mCRC) and represent a routinely used negative predictive indicator in clinical practice.(9) However, 35%–45% of wild-type RAS mCRC patients still do not respond to this treatment and therefore othe…”
Tsujii, Y., Hayashi, Y., Maekawa, A., Fujinaga, T., Nagai, K., Yoshii, S., Sakatani, A., Hiyama, S., Shinzaki, S., Iijima, H., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3147-2 · Cited by 19
“Recently, antiepidermal growth factor receptor (EGFR) monoclonal antibodies such as cetuximab or panitumumab have provided clinical benefit in patients with KRAS wildtype CRC [9, 10].”
BackgroundKim, J. S., Kim, J. E., Kim, K., Lee, J., Park, J. O., Lim, H. Y., Park, Y. S., Kang, W. K., & Kim, S. T. (2017) · Journal of Cancer · doi:10.7150/jca.19458 · Cited by 17
“Nevertheless, about 50% of mCRC patients with all wild-type RAS still do not respond to anti-EGFR treatments [6, 7].”
BackgroundTanioka, H., Asano, M., Yoshida, R., Waki, N., Uno, F., Ishizaki, M., Yamashita, K., Morishita, Y., & Nagasaka, T. (2018) · Oncology Letters · doi:10.3892/ol.2018.9127 · Cited by 17
“Particularly, cetuximab and panitumumab as standard combination chemotherapy regimens in first‑line treatment have led to a marked improvement in clinical outcomes for patients with Ras wild-type mCRC (5,6).”
Clinical validation of coexisting driver mutations in colorectal cancers
Zheng, G., Tseng, L., Haley, L. M., Ibrahim, J., Bynum, J. P., Xian, R. R., Gocke, C. D., Eshleman, J. R., & Lin, M. (2018) · Human Pathology · doi:10.1016/j.humpath.2018.11.014 · Cited by 18
“Anti-EGFR monoclonal antibodies have been approved by the Food and Drug Administration (FDA) in the United States for targeted therapy of metastatic colorectal cancer (CRC) with wild-type KRAS and NRAS genes [1, 2].”
BackgroundUnim, B., Pitini, E., Vito, C. D., D’Andrea, E., Marzuillo, C., & Villari, P. (2019) · Value in Health · doi:10.1016/j.jval.2019.07.009 · Cited by 17
“The importance of predictive genetic testing using RAS gene mutation status before therapy with monoclonal antibodies has been unequivocally demonstrated: clinical trials show that mCRC patients with KRAS mutations do not respond to anti-EGFR therapy,(6,7) and the therapy may negatively affect PFS and overall survival…”
MethodShuford, R. A., Cairns, A., & Moaven, O. (2020) · Cancers · doi:10.3390/cancers12113481 · Cited by 18
“2 months) with FOLFOX and panitumumab in comparison to FOLFOX alone after a post hoc evaluation with extending KRAS mutations [27,28].”
MethodNegative Predictive Biomarkers in Colorectal Cancer: PRESSING Ahead
Sundar, R., Tan, I. B. H., & Chee, C. E. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01977 · Cited by 19
Graham, C. N., Maglinte, G. A., Schwartzberg, L. S., Price, T. J., Knox, H. N., Hechmati, G., Hjelmgren, J., Barber, B., & Fakih, M. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.03.023 · Cited by 16
Cann, C., LaPelusa, M. B., Cimino, S. K., & Eng, C. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1176950 · Cited by 17
“Importantly, PFS was found to be worse in patients whose tumor harbored a KRAS/NRAS mutation (11, 21).”
BackgroundWaldstein, S., Spengler, M., Pinchuk, I. V., & Yee, N. S. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13071114 · Cited by 22
“The PRIME study similarly showed the benefit of panitumumab in addition to chemotherapy in this population [36].”
MethodMolecular profiling in the treatment of colorectal cancer: focus on regorafenib
Grothey, A. A., & Yan, Y. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s79145 · Cited by 19
“In KRAS wt patients, favorable effects of anti-EGFR mAbs on OS, PFS, and overall response rate (ORR) were observed in patients with wt BRAF CRC compared to BRAF mutants.(4,5,24) Additionally, according to a recent meta-analysis examining the impact of cetuximab and panitumumab in BRAF-mutated mCRC patients, there is n…”
Neoadjuvant Chemotherapy Without Radiotherapy for Locally Advanced Rectal Cancer
Sclafani, F., & Cunningham, D. (2014) · Future Oncology · doi:10.2217/fon.14.127 · Cited by 18
Self-citationKarthaus, M., Hofheinz, R., Mineur, L., Letocha, H., Greil, R., Thaler, J., Fernebro, E., Oliner, K. S., Boedigheimer, M. J., Twomey, B., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.343 · Cited by 16
“Bokemeyer C, Köhne CH, Ciardiello F, Lenz HJ, Heinemann V, Klinkhardt U, Beier F, Duecker K, van Krieken JH, Tejpar S (2015) FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer.”
BackgroundMethodResultSelf-citationMolecular dissection of effector mechanisms of RAS-mediated resistance to anti-EGFR antibody therapy
Kasper, S., Reis, H., Ziegler, S., Nothdurft, S., Mueller, A. M., Goetz, M., Wiesweg, M., Phasue, J., Ting, S. C., Wieczorek, S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17438 · Cited by 18
de Macêdo, M. P., de Melo, F. M., Ribeiro, H. S. C., Marques, M. C., Kagohara, L. T., Begnami, M. D., Neto, J. C., Ribeiro, J. S., Soares, F. A., Carraro, D. M., et al. (2017) · Europe PMC (PubMed Central) · Cited by 19
Prospective Biomarker Study in Advanced RAS Wild-Type Colorectal Cancer: POSIBA Trial (GEMCAD 10-02)
García‐Albéniz, X., Alonso, V., Escudero, P., Méndez, M., Gallego-Plazas, J., Rodríguez, J. R., Salud, A., Fernández-Plana, J., Manzano, H., Zanui, M., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0728 · Cited by 18
“Douillard, 2014 [4] RAS Retrospective Prospective RCT positive NA”
BackgroundMethodNiogret, J., Limagne, E., Thibaudin, M., Blanc, J., Bertaut, A., Malicot, K. L., Rinaldi, Y., Caroli‐Bosc, F., Audemar, F., Nguyen, S., et al. (2020) · Cancers · doi:10.3390/cancers12061429 · Cited by 18
“RAS mutational status predicts the absence of efficacy of EGFR antibody therapies in mCRC [10,11].”
BackgroundMazard, T., Cayrefourcq, L., Perriard, F., Senellart, H., Linot, B., de la Fouchardière, C., Terrebonne, É., François, É., Obled, S., Guimbaud, R., et al. (2021) · Cancers · doi:10.3390/cancers13122966 · Cited by 17
“Although the RAS oncogene’s mutational status is an unquestionable marker to select patients who are unlikely to benefit from EGFR antibody therapy [6,7], robust biomarkers for predicting outcome and early treatment response are still lacking, especially for bevacizumab-based regimens [8].”
BackgroundSaravani, K., Salarzaei, M., & Parooie, F. (2021) · Human Antibodies · doi:10.3233/hab-210451 · Cited by 16
Mauri, G., Durinikova, E., Amatu, A., Tosi, F., Cassingena, A., Rizzetto, F., Buzo, K., Arcella, P., Aquilano, M. C., Bonoldi, E., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.21.00143 · Cited by 23
Self-citationA Real-World Application of Liquid Biopsy in Metastatic Colorectal Cancer: The Poseidon Study
Procaccio, L., Bergamo, F., Daniel, F., Rasola, C., Munari, G., Biason, P., Crucitta, S., Barsotti, G., Zanella, G., Angerilli, V., et al. (2021) · Cancers · doi:10.3390/cancers13205128 · Cited by 16
“RAS mutational status represents a criterion for selecting patients who would benefit from anti-EGFR therapy because these drugs are effective [7,8] and registered in RAS wild-type patients only, by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA).”
BackgroundKumar, N., Verma, R., Chen, C., Lu, C. Y., Fu, P., Willis, J. E., & Madabhushi, A. (2022) · The Journal of Pathology · doi:10.1002/path.5864 · Cited by 19
“The majority of CC recurrences are lethal [51].”
BackgroundIn vitro cultures of circulating tumor cells: a potential tool to unravel drug sensitivity
Renzi, G. D., Marco, G. D., Meo, M. D., Rosso, E. D., Gazzaniga, P., & Nicolazzo, C. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2021.121 · Cited by 21
Tumor Biomarker Testing for Metastatic Colorectal Cancer: a Canadian Consensus Practice Guideline
Yu, I. S., Aubin, F., Goodwin, R. A., Loree, J. M., Mather, C. A., Sheffield, B. S., Snow, S. L., & Gill, S. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221111705 · Cited by 18
de Moraes, F. C. A., Pessôa, F. D. D. L., Ribeiro, C. H. D. D. C., Fernandes, M. R., Burbano, R. M. R., & dos Santos, N. P. C. (2024) · BMC Cancer · doi:10.1186/s12885-024-12447-8 · Cited by 18
“73; 95% CI 0.57– 0.93; p = 0.011) [42, 43].”
InfluentialPiton, N., Lonchamp, E., Nowak, F., & Sabourin, J. (2015) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-15-0059 · Cited by 17
Precision Treatment and Prevention of Colorectal Cancer—Hope or Hype?
Muller, C., Yurgelun, M. B. B., & Kupfer, S. S. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.09.046 · Cited by 17
Colorectal Cancer Modeling with Organoids: Discriminating between Oncogenic RAS and BRAF Variants
Post, J. B., Roodhart, J. M. L., & Snippert, H. J. G. (2020) · Trends in cancer · doi:10.1016/j.trecan.2019.12.005 · Cited by 18
Beyond Exon 2 — The Developing Story of RAS Mutations in Colorectal Cancer
Berlin, J. D. (2013) · New England Journal of Medicine · doi:10.1056/nejme1307992 · Cited by 17
Boleij, A., Initiative, D. R. E., Tops, B. B. J., Rombout, P. D. M., Dequeker, E. M., Ligtenberg, M. J. L., & van Krieken, J. H. (2015) · Oncotarget · doi:10.18632/oncotarget.3804 · Cited by 15
Liu, Q., Xi, Y., He, G., Li, X., & Zhan, F. (2021) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-21-716 · Cited by 15
Matteucci, L., Bittoni, A., Gallo, G., Ridolfi, L., & Passardi, A. (2023) · Cancers · doi:10.3390/cancers15215189 · Cited by 19
Metadata
- Authors
- Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., Rivera, F., Kocákova, I., Ruff, P., Błasińska-Morawiec, M., Šmakal, M., Canon, J. L., Rother, M., Williams, R., Rong, A., Wiezorek, J., Sidhu, R., & Patterson, S. D.
- Affiliations
- Institut de Cancérologie de l'Ouest (FR)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-09-12
- Volume
- 369
- Issue
- 11
- Pages
- 1023-1034
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2085633477
- Cited by
- 2,263
- References
- 31
- Citations by year
- 2026: 67 · 2025: 98 · 2024: 110 · 2023: 113 · 2022: 125 · 2021: 203 · 2020: 159 · 2019: 178 · 2018: 181 · 2017: 228 · 2016: 251 · 2015: 290 · 2014: 239 · 2013: 16
- FWCI
- 142.05
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Digital Access to Libraries (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- panitumumab, FOLFOX4, metastatic colorectal cancer, RAS mutations, KRAS exon 2, NRAS, BRAF mutation, anti-EGFR therapy, predictive biomarkers, progression-free survival, overall survival, oxaliplatin, 5-fluorouracil, leucovorin, treatment efficacy and safety, prognostic factors, combination chemotherapy
- MeSH terms
- Panitumumab, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Leucovorin, Fluorouracil, Humans, Membrane Proteins, Mutation, Neoplasm Metastasis, Organoplatinum Compounds, Proto-Oncogene Proteins, Genes, ras, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), Disease-Free Survival, ras Proteins, GTP Phosphohydrolases, Proto-Oncogene Proteins B-raf, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.